Unlocking Insights for Underrepresented Patients: The Role of Real-World Evidence in Addressing Limitations of CDK4/6 Inhibitor RCTs

Summary: Host: Adam Brufsky, MD, PhD <br> <p>This program focuses on increasing clinician familiarity and comfort with real-world evidence (RWE) of CDK4/6 inhibitors in metastatic breast cancer (MBC) and clinicians’ confidence in their ability to discuss RWE with their patients. </p>